Odyssey raises more than $300M as biotech goes public

Odyssey Therapeutics pulled together $279 million from its initial public offering, the autoimmune disease drug developer said Thursday night. Odyssey began trading on the Nasdaq on Friday. The biotech sold 15.5 million shares {$ODTX} at ...